Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 22Terminated 4Withdrawn 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 8Neoplasms 2Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Advanced Solid Tumors 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Lapatinib × Clear all
NCT01985893 2016-01-14

THOR

Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01700010 2013-01-17

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡